Bioresorbable Coronary Stents Market Advancing Heart Therapy

Revenue, 2025

USD 171.83 Million

Forecast, 2035

USD 257.8 Million

CAGR, 2026-2035

4.14%

Report Coverage

Global

Bioresorbable Coronary Stents Market Size, Key Players with Trends and Dynamics

The bioresorbable coronary stents market size was estimated at USD 171.83 million in 2025 and is predicted to increase from USD 178.94 million in 2026 to approximately USD 257.8 million by 2035, expanding at a CAGR of 4.14% from 2026 to 2035.

The bioresorbable coronary stents market is shaped by the increasing prevalence of cardiovascular diseases and growing preference for minimally invasive cardiovascular interventions. Key trends include technological advancements in bioresorbable scaffold materials and expanding use in hospitals and cardiac centers worldwide. North America has been a leading regional market due to well-established healthcare infrastructure, high adoption of innovative stenting technologies, and significant clinical procedure volumes, reinforcing its dominant position.

Key Takeaways

• Bioresorbable coronary stents sector pushed the market to USD 178.94 million by 2026.
• Long-term projections show USD 257.8 million valuation by 2035.
• Growth is expected at a steady CAGR of 4.14% in between 2026 to 2035.
• North America held a major revenue share of approximately 37% of the bioresorbable coronary stents market in 2025.
• Asia-Pacific is expected to witness the fastest CAGR of approximately 18% during the predicted timeframe.
• By stent type, the polymer-based bioresorbable stents segment registered its dominance over the global market with a share of approximately 60% in 2025.
• By stent type, the metallic bioresorbable stents segment is expected to grow with the highest CAGR of approximately 17% in the market during the studied years.
• By material, the PLLA-based stents segment held the largest revenue share of approximately 50% in the bioresorbable coronary stents market in 2025.
• By material, the magnesium alloy-based segment is expected to show the fastest growth with a CAGR of approximately 20% over the forecast period.
• By application/indication, the stable angina segment held a dominant presence in the market with a share of approximately 55% in 2025.
• By application/indication, the Acute Myocardial Infarction (AMI) segment is expected to witness the fastest growth in the market with a CAGR of approximately 17% over the forecast period.
• By procedure type, the elective PCI procedures segment registered its dominance over the global bioresorbable coronary stents market with a share of approximately 60% in 2025.
• By procedure type, the emergency PCI/acute interventions segment is expected to grow with the highest CAGR of approximately 18% in the market during the studied years.

Executive Summary Table

The Future of Coronary Care: Rise of Bioresorbable Stents

A bioresorbable coronary stent is a temporary vascular scaffold placed in a narrowed coronary artery to restore blood flow and then gradually dissolves or is absorbed by the body once the vessel heals, unlike traditional permanent metallic stents that remain indefinitely. These stents reduce long-term complications and support normal vessel function after resorption, addressing clinical concerns such as late thrombosis and chronic inflammation.

The global bioresorbable coronary stents market is being driven by the rising prevalence of cardiovascular diseases, the growing preference for minimally invasive procedures, and continuous technological innovations that improve material biocompatibility and performance. Adoption is increasing as interventional cardiologists favour devices that support healing and reduce lifelong foreign body presence, contributing to market expansion.

AI-Driven Precision in the Evolution of Bioresorbable Coronary Stents

AI integration can significantly improve the bioresorbable coronary stents industry by enhancing stent design, clinical decision-making, and manufacturing efficiency. Machine learning models help optimize material composition, strut thickness, and degradation rates to improve safety and performance. AI-powered imaging and predictive analytics support precise patient selection, reducing complications and improving outcomes. In manufacturing, AI enables quality control, defect detection, and process optimization, while data-driven insights accelerate research, regulatory compliance, and post-market surveillance across global healthcare systems and long-term clinical innovation worldwide.

Trends & Future Outlook of the Bioresorbable Coronary Stents Market

Advanced Materials Development

Next‑generation polymers and magnesium-based bioresorbable materials are being developed to improve mechanical strength, ensure controlled degradation, and reduce inflammation, enhancing safety, long-term patency, and clinical outcomes compared with earlier stent designs.

Minimally Invasive Procedure Optimization

Advances in delivery systems and catheter technology allow for easier, safer, and more precise stent implantation, reducing procedural complications and promoting faster patient recovery in complex coronary interventions.

Enhanced Imaging and Procedure Guidance

Integration of high-resolution imaging techniques like OCT and IVUS improves lesion assessment, stent positioning, and post-implant monitoring, lowering restenosis risk and enhancing the long-term efficacy of bioresorbable stents.

Regulatory and Clinical Adoption Expansion

Growing clinical evidence, real-world data, and streamlined regulatory pathways are increasing acceptance among cardiologists worldwide, supporting broader adoption of bioresorbable stents for complex and high-risk coronary lesion management.

Increasing rate of number of deaths due to cardiac arrest has driven the growth of the bioresorbable coronary stents market through several clinical and healthcare-system mechanisms.

Major Investments and/or Government Data in the Bioresorbable Coronary Stents Market

• In October 2025, MicroPort MedBot and MicroPort Scientific Corporation reached a milestone in 2025 when global shipments of its coronary stent systems surpassed 10 million units, underscoring major industry adoption and investor confidence. The company also expanded its global cardiovascular platform with a US$680 million merger to strengthen R&D and commercialization efforts.
• In April 2025, in India, the expansion and refinement of the Ayushman Bharat public health insurance scheme in 2025 has improved accessibility for coronary stent procedures and encouraged manufacturers to invest in cost‑effective, high‑quality stent solutions. 

Segmental Insights

Stent Type Insights

Which Stent Type Segment Dominated the Bioresorbable Coronary Stents Market?

The polymer-based bioresorbable stents segment dominates the market with a share of approximately 60% due to its biocompatibility, controlled degradation, and flexibility, allowing easier implantation in complex lesions. They reduce long-term complications, support vessel healing, and enable favourable clinical outcomes, while widespread adoption, technological advancements, and physician familiarity further strengthen their preference over other stent types.

Metallic Bioresorbable Stents

The metallic bioresorbable stents segment is anticipated to be the fastest-growing, with a CAGR of approximately 18% in the market, due to its enhanced radial strength, superior mechanical support, and predictable degradation, which allow treatment of complex coronary lesions. Advancements in magnesium and alloy technologies improve safety and efficacy, while growing clinical acceptance, improved patient outcomes, and ongoing R&D efforts drive rapid adoption and market expansion globally.

Material Insights

Why Did the PLLA-Based Stents Segment Dominate the Bioresorbable Coronary Stents Market?

The PLLA-based stents segment dominates the market with a share of approximately 50% due to its excellent biocompatibility, controlled resorption, and proven clinical performance. Its polymer structure ensures vessel support during healing while minimizing inflammation, thrombosis, and restenosis risks. Widespread adoption, regulatory approvals, and strong physician confidence further reinforce PLLA’s leading position in bioresorbable coronary stent applications.

Magnesium Alloy Based

The magnesium alloy-based segment is estimated to be the fastest-growing in the market, with a CAGR of approximately 20%, due to its rapid, predictable bioresorption, excellent mechanical strength, and reduced risk of late thrombosis. Advancements in alloy formulations enhance safety and support complex lesions, while increasing clinical adoption, ongoing R&D, and favorable patient outcomes drive accelerated growth in the global bioresorbable coronary stent market.

Application/Indication Insights

Which Application/ Indication Segment Led the Bioresorbable Coronary Stents Market?

The stable angina segment dominates the global bioresorbable coronary stent market with a share of approximately 55% due to the high prevalence of chronic coronary artery disease and predictable lesion patterns. Patients benefit from improved vessel healing, reduced long-term complications, and minimally invasive procedures. Widespread clinical adoption, physician familiarity, and favourable treatment outcomes further reinforce this segment’s leading position.

Acute Myocardial Infarction (AMI)

The acute myocardial infarction (AMI) segment is anticipated to be the fastest-growing in the market, with a CAGR of approximately 17% due to the rising incidence of heart attacks and demand for rapid, effective coronary intervention. Bioresorbable stents provide temporary vessel support, reduce long-term complications, and enable faster recovery. Increased clinical adoption, advancements in stent technology, and improved patient outcomes drive rapid growth in this segment.

Procedure Type Insights

Which Factors Make Elective PCI Procedures the Dominant Segment in the Market?

The elective PCI procedures segment dominated the bioresorbable coronary stents market with a share of approximately 60% due to planned, non-emergency interventions allowing precise stent selection and placement. These procedures ensure optimal patient outcomes, reduce complication risks, and provide controlled recovery. Growing physician confidence, technological advancements, and widespread adoption of minimally invasive techniques further reinforce this segment’s leading position.

Emergency PCI/Acute Interventions

The emergency PCI/acute interventions segment is estimated to be the fastest-growing, with a CAGR of approximately 18% in the market due to the increasing prevalence of acute coronary events and demand for immediate revascularization. Bioresorbable stents provide temporary vessel support, reduce long-term complications, and enable rapid patient recovery. Advancements in stent design, growing clinical adoption, and improved procedural outcomes are driving rapid growth in this segment.

Regional Distribution

• North America registered dominance in the bioresorbable coronary stents market by 37% in 2025.
• The U.S. led the market by capturing the largest revenue share of the market in 2025.
• Asia Pacific is expected to be the fastest-growing region in the studied years.
• China is anticipated to grow at a rapid CAGR during the forecast period.
• Europe is expected to grow at a significant CAGR in the bioresorbable coronary stents market during the forecast period.
• The UK is anticipated to grow at a rapid CAGR during the forecast period.

Which Factors Made the North America Region the Dominant Region in the Market?

North America dominated the bioresorbable coronary stents market with a share of approximately 37% in 2025. North America dominates the global market due to advanced healthcare infrastructure, high adoption of innovative medical technologies, and the strong presence of key stent manufacturers. Well-established cardiology networks, favourable reimbursement policies, and significant investments in research and development further support widespread clinical adoption and leadership in the region.

The U.S. dominates the North American market due to advanced healthcare infrastructure, high physician awareness, and early adoption of innovative cardiac devices. Strong research and development, supportive regulatory frameworks, widespread clinical trials, and significant investment by leading stent manufacturers further reinforce the country’s leading position in the market.

Which Factors Influence the Fastest Growth of the Asia Pacific Market?

Asia Pacific is estimated to host the fastest-growing bioresorbable coronary stents market with a CAGR of approximately 18% during the forecast period. The Asia-Pacific region is the fastest-growing in the market due to rising cardiovascular disease prevalence, improving healthcare infrastructure, and increasing awareness of minimally invasive cardiac treatments. Growing adoption of advanced stent technologies, expanding medical facilities, and government initiatives supporting cardiac care further drive rapid market growth in the region.

China dominates the Asia-Pacific bioresorbable coronary stents market due to a large patient population, rising incidence of cardiovascular diseases, and expanding healthcare infrastructure. Government support for advanced cardiac treatments, increasing clinical adoption of innovative stent technologies, and significant investments by local and global manufacturers further strengthen China’s leading position in the regional market.

How Big is the Success of Europe in the Market?

Europe is expected to grow at a significant CAGR in the bioresorbable coronary stents market during the forecast period. Europe is a notably growing region in the market due to advanced healthcare systems, high adoption of innovative cardiac devices, and increasing prevalence of cardiovascular diseases. Strong clinical research, favourable regulatory frameworks, and rising physician awareness further support the uptake of bioresorbable stents across key European countries.

The UK is the fastest-growing country in the European bioresorbable coronary stents market due to advanced healthcare infrastructure, growing prevalence of cardiovascular diseases, and early adoption of minimally invasive cardiac technologies. Increased clinical trials, government support for cardiac care, and rising physician awareness further drive the rapid adoption of bioresorbable stents in the country.

Bioresorbable Coronary Stents Market Value Chain Analysis

Research & Development (R&D)

• Research and development involve material selection, stent design, prototype creation, and preclinical testing to ensure safety, biocompatibility, and controlled bioresorption. Engineers and scientists optimize stent structure, strut thickness, and degradation rate to improve performance and reduce complications before human trials.
• Organizations involved: Boston Scientific, Abbott Laboratories, MicroPort Scientific Corporation, Terumo Corporation, and academic cardiovascular research centers.

Clinical Trials & Regulatory Approval

• Clinical trials test the stent in human subjects to assess safety, efficacy, long-term outcomes, and compatibility with complex coronary lesions. This stage includes Phase I–III trials, multi-center studies, and post-procedural monitoring to gather real-world evidence for patient recovery and reduced complications. After successful clinical trials, the stent undergoes regulatory evaluation by authorities such as the FDA, CE Mark bodies, or national agencies. This involves compliance checks, quality audits, risk assessments, and documentation review to ensure the device meets all safety and performance standards before commercialization.
• Organizations involved: Hospitals, interventional cardiology centers, global multicenter clinical research networks, USFDA, CE Mark authorities, and national medical device regulatory agencies.

Patient Support & Services

• Patient support focuses on post-procedure follow-ups, imaging, lifestyle guidance, and adverse event reporting. These services aim to optimize stent performance, ensure long-term cardiovascular health, and provide education and monitoring to patients.
• Organizations involved: Hospitals, cardiology clinics, device distributors, and manufacturer-led patient support programs.

Top Vendors in the Bioresorbable Coronary Stents Market & Their Offerings

SWOT Analysis

Strengths

• Advanced technology: Provides temporary vessel support with natural resorption, reducing long-term complications.
• Clinical benefits: Improves vessel healing, lowers risk of restenosis and thrombosis, and supports minimally invasive procedures.
• Growing adoption: Increasing awareness among cardiologists and patients enhances market penetration globally.

Weaknesses

• High cost: Compared to traditional metallic stents, bioresorbable stents are expensive, limiting accessibility in emerging markets.
• Technical challenges: Issues like limited radial strength, thicker struts, and complex implantation can affect outcomes.
• Limited long-term data: Lack of extensive real-world long-term evidence may restrict physician confidence.

Opportunities

• Technological advancements: Development of magnesium-alloy and polymer-based next-generation stents can improve performance.
• Expanding markets: Growing cardiovascular disease prevalence in the Asia-Pacific and emerging economies increases demand.
• Regulatory support & reimbursement: Government initiatives and health insurance coverage can enhance adoption.

Threats

• Competition from metallic DES: Durable drug-eluting stents remain widely used due to proven long-term performance.
• Stringent regulations: Regulatory hurdles and clinical trial requirements can delay product launches.
• Economic barriers: High device costs and low healthcare spending in certain regions may restrict market growth.

Recent Developments in the Bioresorbable Coronary Stents Market

• In June 2025, research efforts matured with first‑in‑human trials beginning for innovative bioresorbable stents such as STENTiT’s Resorbable Fibrillated Scaffold, aimed at supporting natural tissue regeneration and improving vascular reconstruction approaches.  STENTiT, a medical device company developing a new type of stent with regenerative properties, has revealed the implantation of its Resorbable Fibrillated Scaffold (RFS).
• In October 2025, at EuroPCR 2025, late‑breaking data showed that Elixir Medical’s DynamX Bioadaptor demonstrated significantly lower adverse event rates compared to traditional DES over three years, reinforcing long‑term clinical confidence in bioresorbable platforms.

Segments Covered in the Report

By Stent Type

• Polymer-Based Bioresorbable Stents
• Metallic Bioresorbable Stents (Magnesium / Iron / Alloy)

By Material

• PLLA (Poly-L-Lactic Acid) Based
• PDLLA / Copolymer Based
• Magnesium Alloy Based
• Iron Alloy Based
• Other Bioresorbable Materials

By Application / Indication

• Stable Angina
• Unstable Angina
• Acute Myocardial Infarction (AMI)
• Chronic Total Occlusion (CTO)
• Other CAD Conditions

By Procedure Type

• Elective PCI Procedures
• Emergency PCI / Acute Interventions

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA